Clinical Research Directory
Browse clinical research sites, groups, and studies.
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
Sponsor: Tanta University
Summary
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients. Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT. Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).
Official title: Prothrombin Induced by Vitamin K Absence II (PIVKA-II) Serum Level as a Predictor for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma Patients.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
116
Start Date
2025-01-15
Completion Date
2025-12-31
Last Updated
2025-05-07
Healthy Volunteers
No
Interventions
Prothrombin induced by vitamin K absence II (PIVKA-II)
Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
Locations (1)
Tanta University Hospitals
Tanta, Gharbyea, Egypt